SCHEMBL21629650

SCHEMBL21629650

COC(=O)C1CCCN(C(=O)C(C)Oc2ccc3c(-c4ccccc4)cc(=O)oc3c2)C1

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 1/20 0.65
▸ HPGD P15428 9/20 0.59
▸ ALDH1A1 P00352 9/20 0.59
▸ KDM4E B2RXH2 7/20 0.59
▸ KMT2A Q03164 4/20 0.59
▸ HTT P42858 4/20 0.59
▸ MAPT P10636 1/20 0.59
▸ L3MBTL1 Q9Y468 1/20 0.59
▸ RECQL P46063 2/20 0.52
▸ CYP3A4 P08684 2/20 0.51
▸ CYP2C9 P11712 2/20 0.51
▸ CYP2C19 P33261 2/20 0.51
▸ LMNA P02545 2/20 0.47
▸ USP2 O75604 1/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21629635 1.00 RAB9A (0.65) RAB9AHPGDALDH1A1KDM4EKMT2A
SCHEMBL21629559 1.00 RAB9A (0.65) RAB9AHPGDALDH1A1KDM4EKMT2A
SCHEMBL30056082 0.98 RAB9A (0.62) RAB9AHPGDALDH1A1KDM4EKMT2A
SCHEMBL21629546 0.92 RAB9A (0.68) RAB9AHPGDALDH1A1KDM4EKMT2A
SCHEMBL21629548 0.92 RAB9A (0.68) RAB9AHPGDALDH1A1KDM4EKMT2A
SCHEMBL21629522 0.92 RAB9A (0.68) RAB9AHPGDALDH1A1KDM4EKMT2A
SCHEMBL21629511 0.92 RAB9A (0.68) RAB9AHPGDALDH1A1KDM4EKMT2A
SCHEMBL21629625 0.91 RAB9A (0.62) RAB9AHPGDALDH1A1KDM4EKMT2A
SCHEMBL21648250 0.91 RAB9A (0.62) RAB9AHPGDALDH1A1KDM4EKMT2A
SCHEMBL21629626 0.91 RAB9A (0.62) RAB9AHPGDALDH1A1KDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240252454-A1 COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION LEAD DISCOVERY CENTER GMBH (DE) 2024-08-01 — — US claimed
US-10703735-B2 4-phenyl-coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer LEAD DISCOVERY CENTER GMBH (DE) 2020-07-07 — — US claimed
US-20200031794-A1 4-PHENYL-COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER LEAD DISCOVERY CENTER GMBH (DE) 2020-01-30 — — US claimed
US-20240252454-A1 COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION LEAD DISCOVERY CENTER GMBH (DE) 2024-08-01 — — US disclosed
US-10703735-B2 4-phenyl-coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer LEAD DISCOVERY CENTER GMBH (DE) 2020-07-07 — — US disclosed
US-10703735-B2 4-phenyl-coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer LEAD DISCOVERY CENTER GMBH (DE) 2020-07-07 — — US disclosed
US-20200031794-A1 4-PHENYL-COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER LEAD DISCOVERY CENTER GMBH (DE) 2020-01-30 — — US disclosed
US-20200031794-A1 4-PHENYL-COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER LEAD DISCOVERY CENTER GMBH (DE) 2020-01-30 — — US disclosed
EP-3598972-A1 4-PHENYL-COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER Lead Discovery Center GmbH (DE) 2020-01-29 — — EP disclosed
EP-3598972-A1 4-PHENYL-COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER Lead Discovery Center GmbH (DE) 2020-01-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240252454-A1 COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION TFAM, POLRMT, TUFM RAB9A 4733/4885HPGD 1853/4885ALDH1A1 3415/4885
US-20200031794-A1 4-PHENYL-COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER POLRMT, COX4I1, UQCRC2 RAB9A 4170/4885HPGD 1377/4885ALDH1A1 1344/4885
US-10703735-B2 4-phenyl-coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer POLRMT, COX4I1, UQCRC2 RAB9A 4170/4885HPGD 1377/4885ALDH1A1 1344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback